Search
for
Sort by
Research 31–60 of 1000+
- Smart Responsive Microneedles for Controlled Drug Delivery
- How Advancing is Peripheral Nerve Regeneration Using Nanofiber Scaffolds? A Comprehensive Review of the Literature
- Induced pluripotent stem cell–derived mesenchymal stem cells enhance acellular nerve allografts to promote peripheral nerve regeneration by facilitating angiogenesis
- Phenotyping mice with skin, hair, or nail abnormalities: A systematic approach and methodologies from simple to complex
- Protein Immobilization on Bacterial Cellulose for Biomedical Application
- Scalp microbiome of healthy women wearing hijab compared to those not wearing hijab: a cross-sectional study
- Bacitracin-Loaded Type I Collagen/Bacterial Cellulose Dressing for the Repair of Infected Wounds
- Current Insight of Peptide-Based Hydrogels for Chronic Wound Healing Applications: A Concise Review
- Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
- High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
- Onychomadesis associated with childhood hand-foot-mouth disease
- Specific Attention Areas in Scar Management: Specific Scar Management Depending on Anatomical Features (Face, Hair, Breast, Hand, Joints, Foot)
- Cutaneous toxicities of cancer therapy
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
- Clinical development and management of adverse events associated with FGFR inhibitors
- Cutaneous Reactions to Chemotherapeutic Agents
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
- Cutaneous adverse effects of BRAF inhibitors in metastatic malignant melanoma, a prospective study in 20 patients.
- Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs
- Non-Rash Skin Toxicities Associated with Novel Targeted Therapies
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- Skin toxicity of anti‐cancer therapy
- The incidence and management of cutaneous adverse events of the epidermal growth factor receptor inhibitors
- Cutaneous reactions to targeted therapies in children with CNS tumors: A cross‐sectional study
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma
- Prophylaxis and Management of Skin Toxicities
- Clinical Management of Cutaneous Adverse Events in Patients on Chemotherapy: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology